A seven-ingredient supplement resulted in significant weight and fat mass losses for overweight and/or obese participants. The clinical trial also found improvements in molecular markers of liver health and metabolism.
A seven-ingredient supplement resulted in significant weight and fat mass losses for overweight and/or obese participants. The clinical trial also found improvements in molecular markers of liver health and metabolism.
Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
52-week results from the Phase 3 PaTHway Trial showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer to age-appropriate
Ascendis Pharma (ASND) Presents TransCon PTH Phase 3 52-Week Skeletal Dynamics Data streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.